Latigo Biotherapeutics (LTGO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.55
- Estimate
- -$0.67
- Surprise
- +17.9%
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Latigo Biotherapeutics (LTGO) reported a narrower loss than forecast — adjusted EPS of -$0.55 against the -$0.67 estimate (a 17.9% beat on a still-unprofitable quarter).
Coverage in the report window
- Latigo Biotherapeutics Appoints Todd N. Smith as President and CEO — fiscal.ai, 2026-11-05
- Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-05
- Latigo Biotherapeutics Q3 EPS $(0.55) Beats $(0.58) Estimate — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates LTGO Sell at 5.3/10; no pre/post engine snapshot brackets this report.
1 of the last 2 quarters beat the estimate; this quarter's +17.9% surprise compares with a -2015.5% four-quarter average. Next scheduled report: 2027-03-18.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $52.25 vs price $12.60 — ratio 4.1×). Rejected, falling back to technical TP.
- Quality below floor (2.9 < 4.0)
- Momentum score 3.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.60
- Price target
- $17.32
- Stop
- $11.72
- Upside to target
- +37.5%
Risk check: trading volume is running 2.4× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-08 — shown for context, not personalized investment advice.
LTGO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $835.4M
- P/E (fwd)
- -6.0
- 52-week range
- $10.24–$25.93
- Off 52-week high
- 51.4%
- RSI (14)
- 42
- Volume vs avg
- 2.43×
- Score today
- 5.3/10